These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 37818931)

  • 1. Prevention and treatment of cisplatin-induced ototoxicity in adults: A systematic review.
    Correa-Morales JE; Giraldo-Moreno S; Mantilla-Manosalva N; Cuellar-Valencia L; Borja-Montes OF; Bedoya-Muñoz LJ; Iriarte-Aristizábal MF; Quintero-Muñoz E; Zuluaga-Liberato AM
    Clin Otolaryngol; 2024 Jan; 49(1):1-15. PubMed ID: 37818931
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Medical interventions for the prevention of platinum-induced hearing loss in children with cancer.
    van As JW; van den Berg H; van Dalen EC
    Cochrane Database Syst Rev; 2019 May; 5(5):CD009219. PubMed ID: 31063591
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Medical interventions for the prevention of platinum-induced hearing loss in children with cancer.
    van As JW; van den Berg H; van Dalen EC
    Cochrane Database Syst Rev; 2014 Jul; (7):CD009219. PubMed ID: 24984156
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Medical interventions for the prevention of platinum-induced hearing loss in children with cancer.
    van As JW; van den Berg H; van Dalen EC
    Cochrane Database Syst Rev; 2012 May; (5):CD009219. PubMed ID: 22592737
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Different infusion durations for preventing platinum-induced hearing loss in children with cancer.
    van As JW; van den Berg H; van Dalen EC
    Cochrane Database Syst Rev; 2018 Jul; 7(7):CD010885. PubMed ID: 29975402
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Different infusion durations for preventing platinum-induced hearing loss in children with cancer.
    van As JW; van den Berg H; van Dalen EC
    Cochrane Database Syst Rev; 2016 Aug; (8):CD010885. PubMed ID: 27498707
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Different infusion durations for preventing platinum-induced hearing loss in children with cancer.
    van As JW; van den Berg H; van Dalen EC
    Cochrane Database Syst Rev; 2020 Jan; 1(1):CD010885. PubMed ID: 31961948
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Different infusion durations for preventing platinum-induced hearing loss in children with cancer.
    van As JW; van den Berg H; van Dalen EC
    Cochrane Database Syst Rev; 2014 Jun; (6):CD010885. PubMed ID: 24968257
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Global burden of ototoxic hearing loss associated with platinum-based cancer treatment: A systematic review and meta-analysis.
    Dillard LK; Lopez-Perez L; Martinez RX; Fullerton AM; Chadha S; McMahon CM
    Cancer Epidemiol; 2022 Aug; 79():102203. PubMed ID: 35724557
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incidence of platinum-induced ototoxicity in pediatric patients in Quebec.
    Peleva E; Emami N; Alzahrani M; Bezdjian A; Gurberg J; Carret AS; Daniel SJ
    Pediatr Blood Cancer; 2014 Nov; 61(11):2012-7. PubMed ID: 24976616
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The long-term impacts of hearing loss, tinnitus and poor balance on the quality of life of people living with and beyond cancer after platinum-based chemotherapy: a literature review.
    Phillips OR; Baguley DM; Pearson SE; Akeroyd MA
    J Cancer Surviv; 2023 Feb; 17(1):40-58. PubMed ID: 36637633
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevention of cisplatin-induced ototoxicity in children and adolescents with cancer: a clinical practice guideline.
    Freyer DR; Brock PR; Chang KW; Dupuis LL; Epelman S; Knight K; Mills D; Phillips R; Potter E; Risby D; Simpkin P; Sullivan M; Cabral S; Robinson PD; Sung L
    Lancet Child Adolesc Health; 2020 Feb; 4(2):141-150. PubMed ID: 31866182
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Medical interventions for the prevention of platinum-induced hearing loss in children with cancer.
    van As JW; van den Berg H; van Dalen EC
    Cochrane Database Syst Rev; 2016 Sep; 9(9):CD009219. PubMed ID: 27669661
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term auditory follow-up in the management of pediatric platinum-induced ototoxicity.
    Fetoni AR; Brigato F; De Corso E; Lucidi D; Sergi B; Scarano E; Galli J; Ruggiero A
    Eur Arch Otorhinolaryngol; 2022 Oct; 279(10):4677-4686. PubMed ID: 35024956
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Usefulness of current candidate genetic markers to identify childhood cancer patients at risk for platinum-induced ototoxicity: Results of the European PanCareLIFE cohort study.
    Langer T; Clemens E; Broer L; Maier L; Uitterlinden AG; de Vries ACH; van Grotel M; Pluijm SFM; Binder H; Mayer B; von dem Knesebeck A; Byrne J; van Dulmen-den Broeder E; Crocco M; Grabow D; Kaatsch P; Kaiser M; Spix C; Kenborg L; Winther JF; Rechnitzer C; Hasle H; Kepak T; van der Kooi AF; Kremer LC; Kruseova J; Bielack S; Sorg B; Hecker-Nolting S; Kuehni CE; Ansari M; Kompis M; van der Pal H; Parfitt R; Deuster D; Matulat P; Tillmanns A; Tissing WJE; Beck JD; Elsner S; Am Zehnhoff-Dinnesen A; van den Heuvel-Eibrink MM; Zolk O;
    Eur J Cancer; 2020 Oct; 138():212-224. PubMed ID: 32905960
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cancer survivors treated with platinum-based chemotherapy affected by ototoxicity and the impact on quality of life: a narrative synthesis systematic review.
    Pearson SE; Taylor J; Patel P; Baguley DM
    Int J Audiol; 2019 Nov; 58(11):685-695. PubMed ID: 31545660
    [No Abstract]   [Full Text] [Related]  

  • 17. Molecular Characteristics of Cisplatin-Induced Ototoxicity and Therapeutic Interventions.
    Tan WJT; Vlajkovic SM
    Int J Mol Sci; 2023 Nov; 24(22):. PubMed ID: 38003734
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Platinum-induced ototoxicity in children: a consensus review on mechanisms, predisposition, and protection, including a new International Society of Pediatric Oncology Boston ototoxicity scale.
    Brock PR; Knight KR; Freyer DR; Campbell KC; Steyger PS; Blakley BW; Rassekh SR; Chang KW; Fligor BJ; Rajput K; Sullivan M; Neuwelt EA
    J Clin Oncol; 2012 Jul; 30(19):2408-17. PubMed ID: 22547603
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Determinants of ototoxicity in 451 platinum-treated Dutch survivors of childhood cancer: A DCOG late-effects study.
    Clemens E; de Vries AC; Pluijm SF; Am Zehnhoff-Dinnesen A; Tissing WJ; Loonen JJ; van Dulmen-den Broeder E; Bresters D; Versluys B; Kremer LC; van der Pal HJ; van Grotel M; van den Heuvel-Eibrink MM;
    Eur J Cancer; 2016 Dec; 69():77-85. PubMed ID: 27821322
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Platinum-induced ototoxicity in pediatric cancer survivors: GSTP1 c.313A>G variant association.
    Sherief LM; Rifky E; Attia M; Ahmed R; Kamal NM; Oshi MAM; Hanna D
    Medicine (Baltimore); 2022 Nov; 101(45):e31627. PubMed ID: 36397425
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.